[go: up one dir, main page]

AU2001278913A1 - Method for preventing and/or decreasing amyloid production with polycyclic compounds - Google Patents

Method for preventing and/or decreasing amyloid production with polycyclic compounds

Info

Publication number
AU2001278913A1
AU2001278913A1 AU2001278913A AU7891301A AU2001278913A1 AU 2001278913 A1 AU2001278913 A1 AU 2001278913A1 AU 2001278913 A AU2001278913 A AU 2001278913A AU 7891301 A AU7891301 A AU 7891301A AU 2001278913 A1 AU2001278913 A1 AU 2001278913A1
Authority
AU
Australia
Prior art keywords
preventing
polycyclic compounds
amyloid production
decreasing amyloid
decreasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278913A
Inventor
Yuanbin Liu
David R. Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of AU2001278913A1 publication Critical patent/AU2001278913A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001278913A 2000-07-17 2001-07-13 Method for preventing and/or decreasing amyloid production with polycyclic compounds Abandoned AU2001278913A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/617,147 2000-07-17
US09/617,147 US6472436B1 (en) 2000-07-17 2000-07-17 Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
PCT/US2001/022122 WO2002005813A2 (en) 2000-07-17 2001-07-13 Method for preventing and/or decreasing amyloid production with polycyclic compounds

Publications (1)

Publication Number Publication Date
AU2001278913A1 true AU2001278913A1 (en) 2002-01-30

Family

ID=24472451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278913A Abandoned AU2001278913A1 (en) 2000-07-17 2001-07-13 Method for preventing and/or decreasing amyloid production with polycyclic compounds

Country Status (3)

Country Link
US (2) US6472436B1 (en)
AU (1) AU2001278913A1 (en)
WO (1) WO2002005813A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479482B2 (en) * 2001-11-21 2009-01-20 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
CA2473102A1 (en) * 2002-01-29 2003-07-29 Protemix Corporation Limited Suppression of cytotoxic protein conformers
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
WO2005000193A2 (en) * 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
PT1511710E (en) * 2002-05-31 2014-02-26 Proteotech Inc Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer s disease, type 2 diabetes, and parkinson s disease
AU2003261834A1 (en) * 2002-08-30 2004-05-04 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP1583713B1 (en) * 2003-01-07 2009-03-25 Ramot at Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
CA2540407A1 (en) * 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
WO2008005577A2 (en) * 2006-07-07 2008-01-10 University Of South Florida Compositions of polyphenols and methods of use
US8778986B1 (en) * 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
RU2009134137A (en) * 2007-02-14 2011-03-27 Марс, Инкорпорейтед (Us) NEUROGENIC COMPOUNDS
WO2008109517A1 (en) * 2007-03-02 2008-09-12 University Of South Florida Neurodegenerative disease treatment using jak/stat inhibition
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
EP2307342B1 (en) 2008-07-02 2017-06-21 British Columbia Cancer Agency Branch Diglycidic ether derivative therapeutics and methods for their use
JP5940982B2 (en) * 2010-01-06 2016-06-29 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ Bisphenol derivatives and their use as androgen receptor activity modulators
US20150065449A1 (en) 2011-08-12 2015-03-05 Florida State University Research Foundation, Inc. Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
BR112015028174A2 (en) 2013-05-10 2017-07-25 British Columbia Cancer Agency Branch compound, pharmaceutical composition, use of a pharmaceutical composition, and methods for modulating androgen receptor activity and for increasing the bioavailability of an androgen receptor modulator
KR20160054523A (en) 2013-09-09 2016-05-16 브리티쉬 콜롬비아 캔써 에이전시 브랜치 Halogenated compounds for cancer imaging and treatment and methods for their use
DK3988541T3 (en) 2015-01-13 2024-09-16 British Columbia Cancer Agency Branch HETEROCYCLIC COMPOUNDS FOR IMAGING AND TREATMENT OF CANCER AND METHODS OF USING THESE
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
PE20211543A1 (en) 2018-10-18 2021-08-16 Essa Pharma Inc ANDROGEN RECEIVER MODULATORS AND METHODS FOR THEIR USE
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
US20210323931A1 (en) 2020-04-17 2021-10-21 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3408407A (en) * 1964-03-27 1968-10-29 Union Carbide Corp Novel bisphenols of cyclohexadiene
KR900012875A (en) * 1989-02-08 1990-09-03 오스카 아끼히꼬 A biphenyl derivative, a neuronal cell-denatured restoration or protection agent, and a method for producing a cuneyl derivative used therein
EP0688327B1 (en) * 1993-03-01 1999-05-06 Glycan Pharmaceuticals, Inc. Analogs for specific oligosaccharide-protein interactions and uses therefor
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
JPH08268949A (en) * 1995-03-29 1996-10-15 Eisai Co Ltd Diphenylmethylene derivative
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
JPH11510144A (en) * 1995-07-24 1999-09-07 ユニバーシティー・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド Use of non-estrogenic polycyclic phenolic compounds for the manufacture of a medicament for imparting neuroprotection to cells
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
FR2753969B1 (en) * 1996-09-27 1998-10-30 Adir NOVEL FLAVON DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
JP2002501018A (en) * 1998-01-26 2002-01-15 マイトコー Mitochondrial protective agents for treating mitochondrial-related diseases
FR2778337B1 (en) * 1998-05-05 2001-08-31 Inst Nat Sante Rech Med ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS
AU5531599A (en) * 1998-09-01 2000-03-21 Lg Chemical Ltd. Novel cdk inhibitors having flavone structure
CN1326450A (en) * 1998-09-24 2001-12-12 三菱化学株式会社 Hydroxyflavone Derivatives as Tau Kinase 1 Inhibitors

Also Published As

Publication number Publication date
US6472436B1 (en) 2002-10-29
WO2002005813A3 (en) 2003-07-10
WO2002005813A2 (en) 2002-01-24
US7053116B2 (en) 2006-05-30
US20030096859A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
AU2001278913A1 (en) Method for preventing and/or decreasing amyloid production with polycyclic compounds
AU2002212112A1 (en) Profile composite component and method for the production thereof
AU2001266072A1 (en) Flat gasket and method for the production thereof
AU2001256755A1 (en) Biosensor and method for manufacturing the same
AU2001266583A1 (en) Epothilone derivatives and methods for making and using the same
AU2002338336A1 (en) Epothilone derivatives and methods for making and using the same
AU2002250858A1 (en) Capsule-in-capsule system and method for the production thereof
AU4455601A (en) Hole structure and production method for hole structure
AU2001293753A1 (en) Method for the production of macrocyclic esters
AU2001280270A1 (en) Method of manufacturing structural members and the members provided by such method
AU5057600A (en) Component and method for the production thereof
AU2003297177A1 (en) Spliced yarn and method for forming the same
AU2002241739A1 (en) Antimycobacterial compounds and method for making the same
AU4284500A (en) Multilayer membranes and method for the production thereof
AU2001291288A1 (en) Webpad and method for using the same
AU2000267048A1 (en) Bases for cutout circuits and method for the production thereof
AU4751300A (en) Method and device for the continuous production of NaAlCl4 or NaFeCl4
AU2001289844A1 (en) Amifostine-monohydrate and a method for the production thereof
AU2002221190A1 (en) Paper quilt and method for manufacturing the same
AU2001274004A1 (en) Method for the production of 2- coumarone and substituted 2-coumarones
AU4645401A (en) Flat composite component and method for the production thereof
IL152795A0 (en) Method for the production of 2-coumarone and substituted 2-coumarones
AU4235201A (en) Indentor and method for producing the same
AU2001260184A1 (en) Connection device and method for the production thereof
AU2001292825A1 (en) Webpad and method for using the same